Yüklüyor......
Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease
BACKGROUND: Alectinib, a second-generation anaplastic lymphoma kinase (ALK) inhibitor, is a key drug for ALK rearranged lung adenocarcinoma. Interstitial lung disease (ILD) is an important adverse effect of alectinib, which generally requires termination of treatment. However, we treated two patient...
Kaydedildi:
| Yayımlandı: | BMC Pulm Med |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5718064/ https://ncbi.nlm.nih.gov/pubmed/29207989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-017-0519-y |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|